login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BEAM THERAPEUTICS INC (BEAM) Stock News
USA
-
Nasdaq
- NASDAQ:BEAM -
US07373V1052
-
Common Stock
27.83
USD
+0.43 (+1.57%)
Last: 12/11/2025, 11:43:57 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BEAM Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Zacks Investment Research
- Mentions:
EDIT
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?
5 days ago - By: Beam Therapeutics
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
3 months ago - By: Benzinga
Is Beam Therapeutics Gaining or Losing Market Support?
5 days ago - By: Beam Therapeutics
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
7 days ago - By: Zacks Investment Research
- Mentions:
REGN
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?
13 days ago - By: Zacks Investment Research
- Mentions:
REGN
NTLA
CRSP
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
14 days ago - By: The Motley Fool
Beam Therapeutics (BEAM) Earnings Transcript
14 days ago - By: Zacks Investment Research
- Mentions:
REGN
NTLA
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
20 days ago - By: Zacks Investment Research
- Mentions:
REGN
NTLA
CRSP
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
a month ago - By: Zacks Investment Research
- Mentions:
REGN
NTLA
CRSP
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
a month ago - By: Beam Therapeutics
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
a month ago - By: Beam Therapeutics
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
a month ago - By: Zacks Investment Research
- Mentions:
REGN
FOLD
RARE
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
a month ago - By: Zacks Investment Research
- Mentions:
FOLD
ANIP
MDGL
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
a month ago - By: Zacks Investment Research
- Mentions:
NVO
LLY
FOLD
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
a month ago - By: Benzinga
- Mentions:
ADPT
COIN
ARKW
ARKK
...
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys
a month ago - By: Zacks Investment Research
- Mentions:
FOLD
ZTS
ANIP
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
a month ago - By: Zacks Investment Research
- Mentions:
NBIX
FOLD
XENE
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
a month ago - By: Zacks Investment Research
- Mentions:
IMTX
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates
a month ago - By: Beam Therapeutics
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
a month ago - By: Beam Therapeutics
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
a month ago - By: Zacks Investment Research
- Mentions:
VRTX
NTLA
CRSP
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
a month ago - By: Beam Therapeutics
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
a month ago - By: Zacks Investment Research
- Mentions:
FOLD
ANIP
APLS
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
a month ago - By: Zacks Investment Research
- Mentions:
AGIO
ANIP
NTLA
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
a month ago - By: Zacks Investment Research
- Mentions:
ALNY
FOLD
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
a month ago - By: Zacks Investment Research
- Mentions:
AMRN
ANIP
CRMD
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
a month ago - By: Zacks Investment Research
Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2 months ago - By: Zacks Investment Research
Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross
2 months ago - By: Zacks Investment Research
- Mentions:
REGN
NTLA
CRSP
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Please enable JavaScript to continue using this application.